PayerTalkCE™ Presents: Understanding Best Practices in Access to Pediatric Dermatologic Care for Children Living with Atopic Dermatitis

Release Date: October 1, 2023
Expiration Date: March 31, 2025
Estimated Time to Complete Activity: 0.5 hours
Compatible with all modern browsers and mobile devices

Expert Faculty Presenters:


	Gary M. Owens, MD President Gary Owens Associates, Inc. Click here for biography

	Joy Wan, MD, MSCE Assistant Professor of Dermatology John Hopkins University School of Medicine Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview
A keen understanding of the complex challenges those pediatric patients and their families face when living with atopic dermatitis is critical. With a rapidly evolving atopic dermatitis landscape, payer decision makers need to be kept up-to-date on changes in this area.

Educational Objectives
After completing this activity, the participant should be better able to:

Describe the pediatric patient with atopic dermatitis patient journey
Describe the priorities for assessment and treatment approach for pediatric AD cases
Identify the challenges of treating pediatric patients with AD and accompany comorbidities
Employ strategies that help patients overcome non-clinical barriers to care, including timely referrals to improve outcomes in AD disease management

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE), the National Eczema Association (NEA) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education
PACE designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
PACE designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-23-234-H01-P
Type of Activity: Knowledge

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.

Disclosure of Conflicts of Interest
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

*Faculty*	*Conflicts of Interest*
Gary M. Owens, MD	Consultant/Advisor/Speaker: Sanofi, Regeneron, Incyte, Baxter, CyRx, BD, Sage Therapeutics.
Joy Wan, MD, MSCE	Consultant/Advisor/Speaker: Janssen Researcher: Pfizer Data Monitoring Committee Member: Sun Pharmaceuticals

The PACE planners and managers have nothing to disclose.
The NEA planners and managers have nothing to disclose.
The Impact Education, LLC® planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.